Biogaia AB
STO:BIOG B

Watchlist Manager
Biogaia AB Logo
Biogaia AB
STO:BIOG B
Watchlist
Price: 110.2 SEK 0.64% Market Closed
Market Cap: 11.1B SEK
Have any thoughts about
Biogaia AB?
Write Note

EV/EBIT
Enterprise Value to EBIT

25.1
Current
24.1
Median
4
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
25.1
=
Enterprise Value
10B SEK
/
EBIT
400.5m SEK
All Countries
Close
Market Cap EV/EBIT
SE
Biogaia AB
STO:BIOG B
11.1B SEK 25.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 582.8
US
Abbvie Inc
NYSE:ABBV
318.1B USD 23.9
US
Amgen Inc
NASDAQ:AMGN
142.2B USD 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD 22.7
US
Epizyme Inc
F:EPE
94.1B EUR -499.7
AU
CSL Ltd
ASX:CSL
135.7B AUD 24.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 17.1
US
Seagen Inc
F:SGT
39.3B EUR -52.9
NL
argenx SE
XBRU:ARGX
36.2B EUR -79.9
EBIT Growth EV/EBIT to Growth
SE
Biogaia AB
STO:BIOG B
Average EV/EBIT: 22
25.1
41%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 582.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.9
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.5
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.7 N/A N/A
AU
CSL Ltd
ASX:CSL
24.7
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
25.4
2-Years Forward
EV/EBIT
18.4
3-Years Forward
EV/EBIT
16.1

See Also

Discover More